Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer: ASCO guideline rapid recommendation update

Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer: American Society of Clinical Oncology (ASCO) guideline rapid recommendation update

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

Background: In 2021, ASCO published a guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor–negative. That guideline was updated in August 2022 to incorporate the results of the DESTINY-Breast04 trial. The results of the TROPiCS-02 trial, published on October 10, 2022, provided another signal to update.


Read full Guideline